NurExone Biologic (TSXV: NRX) (Germany: J90)

NurExone Biologic is developing exosome-based therapies to regenerate nerves and recover function after Central Nervous System injuries.

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

https://t.co/AZXDHJMsFd
An MOU with Nanopass will allow evaluation of clinically established MicronJet™ technology with our exosome formulations for optic nerve and skincare applications.
ExoPTEN for acute spinal cord injury continues to advance separately on its existing path.

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

We announced our Q1 2026 financial results and corporate update.

Read the full announcement: https://t.co/ShN2JLOqLC

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

https://t.co/pagzfj0Jox

[Progress, Potential, And Possibilities @ProgressPotent1]

What if paralysis 👨‍🦽 wasn’t permanent - or at least not untreatable?

What if we could deliver regenerative signals to the central nervous system… through a simple intranasal spray?

In our latest @ProgressPotent1 episode, @liorshal (CEO of @NBiologic) breaks down the science behind ExoPTEN - an exosome-based therapy designed to deliver siRNA and temporarily silence the PTEN signaling pathway, one of the nervous system’s key “brakes” on regeneration. 🚀

In preclinical models, this approach has shown something rarely seen in this field: meaningful functional recovery after severe spinal cord injury.

We explore:

- Why the central nervous system struggles to regenerate;
- Whether exosomes can finally solve the delivery problem;
- Dr. Shaltiel’s journey - from ion channel biophysics to leading one of the more ambitious bets in neuroregeneration;

#Biotech #Neuroscience #SpinalCordInjury #RegenerativeMedicine #Exosomes #Neuroregeneration #GeneSilencing #FutureOfMedicine #HealthTech #Longevity
@russopartners @HebrewU

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

Join us at the Water Tower Research LLC Insights Conference, a virtual event for investors seeking direct access to innovative companies.

Register here: https://t.co/yYFbJPBeZ7

NurExone’s session will take place on Tuesday, April 14, at 11:50 AM EST.

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

A really important milestone for NurExone....

Read more: https://t.co/knXfjssOl7

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

Over the past year, the term "exosome" entered mainstream conversation, but much of the visibility came from cosmetic or plant-derived products. The next phase looks very different.

Do you agree that 2026 marks the shift to therapeutic reality for exosomes?

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

Welcoming Eyal Gabbai to our Board!

He brings a strong mix of patient perspective, health-system economics and capital markets experience to help translate strong science into real-world care.

Read more: https://t.co/vKPraOH048

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

⚡ NurExone’s exosomes show significant anti-inflammatory activity, outperforming commercial alternatives in new laboratory analysis!

#Biotech #Exosomes #RegenerativeMedicine #Innovation #NurExone $NRX

Read here: https://t.co/yntSHBIXlO

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

🗞️ Planning Small-Scale ExoPTEN Clinical Manufacturing in Preparation for Future First-in-Human Use Pathways!

#NurExone #ExoPTEN #Exosomes #Biomanufacturing #ClinicalReadiness

Read more: https://t.co/6Ja2tgXMsr

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

@ABCWorldNews @ReeveWill Christopher Reeve really was a Super Man who inspires us with his legacy for patients with spinal cord injuries as we work towards new therapeutic directions

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

https://t.co/mcvtqwgeP2

[Zacks SCR @ZacksSmallCap]

$NRXBF $NRX.V @NBiologic Advances Toward Breakthrough Treatments https://t.co/eZZztT4JXL

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

We released our Q3 results and corporate updates on Friday, highlighting scientific progress, strengthened IP, and continued momentum toward clinical readiness.

Read more: https://t.co/dQ0Vgl3v0e

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

NurExone was nominated for The Galien Foundation Best Bridge Builder Award as we bridge academic research and applied innovation.

#SeeyouinStockholm #GalienPrix #BridgeBuilding
https://t.co/NSjf9ZNMFU

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

NurExone Biologic is pioneering a class of regenerative medicines that harness the body's own communication system to develop therapies with the potential to regenerate, repair & restore nerve function!

#Exosomes #ExoTherapy #BiotechInvesting #SpinalCord

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

https://t.co/4cSKiapoz4

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

The Jerusalem Post highlighted ScienceAbroad’s work connecting thousands of Israeli scientists worldwide, advancing collaboration, mentorship, and the global exchange of ideas.

Thank you Judy Siegel-Itzkovich for the wonderful coverage!

📖 Read here: https://t.co/hsmHZn6GHY

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

Not easy to pick up where nature leaves off, but we are trying our best! Learn more!!

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

Read more about NurExone's Regenerative Therapy for CNS injuries under development: https://t.co/G96sUsilYv